PET/CT in cancer research: From preclinical to clinical applications

S. Del Vecchio, A. Zannetti, R. Fonti, F. Iommelli, L. M. Pizzuti, A. Lettieri, M. Salvatore

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The identification of genetic and biochemical mechanisms underlying tumor growth and progression along with the unraveling of human genoma provided a plethora of new targets for cancer detection, treatment and monitoring. Simultaneously, the extraordinary development of a number of imaging technologies, including hybrid systems, allowed the visualization of biochemical, molecular and physiological aberrations linked to underlying mutations in a given tumor. In vivo evaluation of complex biological processes such as proliferation, apoptosis, angiogenesis, metastasis, gene expression, receptor-ligand interactions, transport of substrates and metabolism of nutrients in human cancers is feasible using PET/CT and radiolabeled molecular probes. Some of these compounds are in preclinical phases of evaluation whereas others have been already applied in clinical settings. Here we provide prominent examples on how some biological processes and target expression can be visualized by PET/CT in animal tumor models and cancer patients for the noninvasive detection of well-known markers of tumor aggressiveness, invasiveness and resistance to treatment and for the evaluation of tumor response to therapy.

Original languageEnglish
Pages (from-to)190-200
Number of pages11
JournalContrast Media and Molecular Imaging
Volume5
Issue number4
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Research
Neoplasms
Biological Phenomena
Molecular Probes
Tumor Biomarkers
Molecular Biology
Therapeutics
Animal Models
Apoptosis
Neoplasm Metastasis
Ligands
Technology
Gene Expression
Food
Mutation
Growth

Keywords

  • Cancer
  • PET/CT
  • Translational research

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Del Vecchio, S., Zannetti, A., Fonti, R., Iommelli, F., Pizzuti, L. M., Lettieri, A., & Salvatore, M. (2010). PET/CT in cancer research: From preclinical to clinical applications. Contrast Media and Molecular Imaging, 5(4), 190-200. https://doi.org/10.1002/cmmi.368

PET/CT in cancer research : From preclinical to clinical applications. / Del Vecchio, S.; Zannetti, A.; Fonti, R.; Iommelli, F.; Pizzuti, L. M.; Lettieri, A.; Salvatore, M.

In: Contrast Media and Molecular Imaging, Vol. 5, No. 4, 07.2010, p. 190-200.

Research output: Contribution to journalArticle

Del Vecchio, S, Zannetti, A, Fonti, R, Iommelli, F, Pizzuti, LM, Lettieri, A & Salvatore, M 2010, 'PET/CT in cancer research: From preclinical to clinical applications', Contrast Media and Molecular Imaging, vol. 5, no. 4, pp. 190-200. https://doi.org/10.1002/cmmi.368
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A et al. PET/CT in cancer research: From preclinical to clinical applications. Contrast Media and Molecular Imaging. 2010 Jul;5(4):190-200. https://doi.org/10.1002/cmmi.368
Del Vecchio, S. ; Zannetti, A. ; Fonti, R. ; Iommelli, F. ; Pizzuti, L. M. ; Lettieri, A. ; Salvatore, M. / PET/CT in cancer research : From preclinical to clinical applications. In: Contrast Media and Molecular Imaging. 2010 ; Vol. 5, No. 4. pp. 190-200.
@article{a3f050a240d4443187f73b672cb4f804,
title = "PET/CT in cancer research: From preclinical to clinical applications",
abstract = "The identification of genetic and biochemical mechanisms underlying tumor growth and progression along with the unraveling of human genoma provided a plethora of new targets for cancer detection, treatment and monitoring. Simultaneously, the extraordinary development of a number of imaging technologies, including hybrid systems, allowed the visualization of biochemical, molecular and physiological aberrations linked to underlying mutations in a given tumor. In vivo evaluation of complex biological processes such as proliferation, apoptosis, angiogenesis, metastasis, gene expression, receptor-ligand interactions, transport of substrates and metabolism of nutrients in human cancers is feasible using PET/CT and radiolabeled molecular probes. Some of these compounds are in preclinical phases of evaluation whereas others have been already applied in clinical settings. Here we provide prominent examples on how some biological processes and target expression can be visualized by PET/CT in animal tumor models and cancer patients for the noninvasive detection of well-known markers of tumor aggressiveness, invasiveness and resistance to treatment and for the evaluation of tumor response to therapy.",
keywords = "Cancer, PET/CT, Translational research",
author = "{Del Vecchio}, S. and A. Zannetti and R. Fonti and F. Iommelli and Pizzuti, {L. M.} and A. Lettieri and M. Salvatore",
year = "2010",
month = "7",
doi = "10.1002/cmmi.368",
language = "English",
volume = "5",
pages = "190--200",
journal = "Contrast Media and Molecular Imaging",
issn = "1555-4309",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - PET/CT in cancer research

T2 - From preclinical to clinical applications

AU - Del Vecchio, S.

AU - Zannetti, A.

AU - Fonti, R.

AU - Iommelli, F.

AU - Pizzuti, L. M.

AU - Lettieri, A.

AU - Salvatore, M.

PY - 2010/7

Y1 - 2010/7

N2 - The identification of genetic and biochemical mechanisms underlying tumor growth and progression along with the unraveling of human genoma provided a plethora of new targets for cancer detection, treatment and monitoring. Simultaneously, the extraordinary development of a number of imaging technologies, including hybrid systems, allowed the visualization of biochemical, molecular and physiological aberrations linked to underlying mutations in a given tumor. In vivo evaluation of complex biological processes such as proliferation, apoptosis, angiogenesis, metastasis, gene expression, receptor-ligand interactions, transport of substrates and metabolism of nutrients in human cancers is feasible using PET/CT and radiolabeled molecular probes. Some of these compounds are in preclinical phases of evaluation whereas others have been already applied in clinical settings. Here we provide prominent examples on how some biological processes and target expression can be visualized by PET/CT in animal tumor models and cancer patients for the noninvasive detection of well-known markers of tumor aggressiveness, invasiveness and resistance to treatment and for the evaluation of tumor response to therapy.

AB - The identification of genetic and biochemical mechanisms underlying tumor growth and progression along with the unraveling of human genoma provided a plethora of new targets for cancer detection, treatment and monitoring. Simultaneously, the extraordinary development of a number of imaging technologies, including hybrid systems, allowed the visualization of biochemical, molecular and physiological aberrations linked to underlying mutations in a given tumor. In vivo evaluation of complex biological processes such as proliferation, apoptosis, angiogenesis, metastasis, gene expression, receptor-ligand interactions, transport of substrates and metabolism of nutrients in human cancers is feasible using PET/CT and radiolabeled molecular probes. Some of these compounds are in preclinical phases of evaluation whereas others have been already applied in clinical settings. Here we provide prominent examples on how some biological processes and target expression can be visualized by PET/CT in animal tumor models and cancer patients for the noninvasive detection of well-known markers of tumor aggressiveness, invasiveness and resistance to treatment and for the evaluation of tumor response to therapy.

KW - Cancer

KW - PET/CT

KW - Translational research

UR - http://www.scopus.com/inward/record.url?scp=77956139255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956139255&partnerID=8YFLogxK

U2 - 10.1002/cmmi.368

DO - 10.1002/cmmi.368

M3 - Article

C2 - 20812287

AN - SCOPUS:77956139255

VL - 5

SP - 190

EP - 200

JO - Contrast Media and Molecular Imaging

JF - Contrast Media and Molecular Imaging

SN - 1555-4309

IS - 4

ER -